1-6 of 6
Chung-Han Lee
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience

Brendan J. Guercio, Michal Sarfaty, Min Yuen Teo, Neha Ratna, Cihan Duzgol, Samuel A. Funt, Chung-Han Lee, David H. Aggen, Ashley M. Regazzi, Ziyu Chen, Michael Lattanzi, Hikmat A. Al-Ahmadie, A. Rose Brannon, Ronak Shah, Carissa Chu, Andrew T. Lenis, Eugene Pietzak, Bernard H. Bochner, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, Dean F. Bajorin, Gopa Iyer
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4586–4595.
https://doi.org/10.1158/1078-0432.CCR-23-1283
Published: 14 November 2023
View article titled, Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience
Open the PDF for Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience in another window
Includes: Supplementary data
Journal Articles

Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade

Yasser Ged, Alejandro Sanchez, Sujata Patil, Andrea Knezevic, Emily Stein, Stacey Petruzella, Kate Weiss, Cihan Duzgol, Joshua Chaim, Oguz Akin, Marina Mourtzakis, Michael T. Paris, Jessica Scott, Fengshen Kuo, Ritesh Kotecha, A. Ari Hakimi, Chung-Han Lee, Robert J. Motzer, Martin H. Voss, Helena Furberg
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (23): 5180–5189.
https://doi.org/10.1158/1078-0432.CCR-22-1389
Published: 01 December 2022
View article titled, Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade
Open the PDF for Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade in another window
Includes: Supplementary data
Journal Articles

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

Chung-Han Lee, Robert Motzer, Hamid Emamekhoo, Marc Matrana, Ivor Percent, James J. Hsieh, Arif Hussain, Ulka Vaishampayan, Sandy Liu, Steven McCune, Vijay Patel, Montaser Shaheen, Johanna Bendell, Alice C. Fan, Benjamin A. Gartrell, Oscar B. Goodman, Jr, Petros G. Nikolinakos, Arash Rezazadeh Kalebasty, Yousef Zakharia, Zhentao Zhang, Hema Parmar, Lalith Akella, Keith Orford, Nizar M. Tannir
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3248–3255.
https://doi.org/10.1158/1078-0432.CCR-22-0061
Published: 02 August 2022
View article titled, Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
Open the PDF for Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial in another window
Includes: Supplementary data
Journal Articles

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Meredith M. Regan, Opeyemi A. Jegede, Charlene M. Mantia, Thomas Powles, Lillian Werner, Robert J. Motzer, Nizar M. Tannir, Chung-Han Lee, Yoshihiko Tomita, Martin H. Voss, Elizabeth R. Plimack, Toni K. Choueiri, Brian I. Rini, Hans J. Hammers, Bernard Escudier, Laurence Albiges, Stephen Huo, Viviana Del Tejo, Brian Stwalley, Michael B. Atkins, David F. McDermott
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6687–6695.
https://doi.org/10.1158/1078-0432.CCR-21-2283
Published: 15 December 2021
View article titled, Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
Open the PDF for Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial in another window
Includes: Supplementary data
Journal Articles

Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma

Kyrollis Attalla, Renzo G. DiNatale, Phillip M. Rappold, Christopher J. Fong, Francisco Sanchez-Vega, Andrew W. Silagy, Stanley Weng, Jonathan Coleman, Chung-Han Lee, Maria I. Carlo, Jeremy C. Durack, Stephen B. Solomon, Victor E. Reuter, Paul Russo, Timothy A. Chan, Robert J. Motzer, Nikolaus D. Schultz, Ed Reznik, Martin H. Voss, A. Ari Hakimi
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5595–5606.
https://doi.org/10.1158/1078-0432.CCR-20-4058
Published: 15 October 2021
View article titled, Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma
Open the PDF for Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase–Deficient Renal Cell Carcinoma

Jack P. Gleeson, Ines Nikolovski, Renzo Dinatale, Mark Zucker, Andrea Knezevic, Sujata Patil, Yasser Ged, Ritesh R. Kotecha, Natalie Shapnik, Samuel Murray, Paul Russo, Jonathan Coleman, Chung Han Lee, Zsofia K. Stadler, A. Ari Hakimi, Darren R. Feldman, Robert J. Motzer, Ed Reznik, Martin H. Voss, Ying-Bei Chen, Maria I. Carlo
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (10): 2910–2919.
https://doi.org/10.1158/1078-0432.CCR-20-4367
Published: 15 May 2021
View article titled, Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Open the PDF for Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase–Deficient Renal Cell Carcinoma in another window
Includes: Supplementary data